Moderna's Stock Soars and Dips After Cancer Vaccine Buzz

Moderna's stock took a wild ride, soaring 177% on exciting news about a cancer vaccine, only to plunge 20% as investors hit the brakes. Merck joined the fun, bouncing around like a rubber ball. With nine more studies lined up, folks are left wondering if this is the start of a big win or just a quick flash of excitement.